3-Methoxyamphetamine

3-Methoxyamphetamine
Clinical data
Other names3-MA; 3-MeO-A; meta-Methoxyamphetamine; MMA
Routes of
administration
Oral
Drug classSerotonin–norepinephrine–dopamine releasing agent; Sympathomimetic
ATC code
  • None
Identifiers
  • 1-(3-methoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H15NO
Molar mass165.236 g·mol−1
3D model (JSmol)
  • NC(C)CC1=CC=CC(OC)=C1
  • InChI=1S/C10H15NO/c1-8(11)6-9-4-3-5-10(7-9)12-2/h3-5,7-8H,6,11H2,1-2H3 checkY
  • Key:VEJWNIYARKAHFI-UHFFFAOYSA-N checkY
  (verify)

3-Methoxyamphetamine (3-MA), also known as meta-methoxyamphetamine (MMA), is a monoamine releasing agent (MRA) of the amphetamine family. It is a positional isomer of para-methoxyamphetamine (PMA; 4-methoxyamphetamine). The drug has been encountered as a novel designer drug.

Use and effects

According to Alexander Shulgin, 3-MA showed no central or psychedelic effects in humans at a total dose of 50 mg (25 mg orally twice separated by 3 hours). However, sympathomimetic effects have occurred with the drug at an oral dose of 25 mg in humans.

Pharmacology

Pharmacodynamics

3-MA is a combined serotonin–norepinephrine–dopamine releasing agent (SNDRA) rather than a fairly selective serotonin releasing agent (SSRA) like the related drug para-methoxyamphetamine (PMA; 4-MA). Its EC50Tooltip half-maximal effective concentration values for induction of monoamine release were reported to be 58 nM for norepinephrine and 103 nM for dopamine in rat brain synaptosomes, whereas the value for serotonin was not reported. The activity of 3-MA as a monoamine oxidase inhibitor (MAOI) has been studied, with it showing less MAOI activity than PMA.

The drug has shown relatively low affinity for serotonin receptors in the rat stomach fundus strip, intermediate between amphetamine and amphetamine psychedelics like DOM and DOB. In another study, its affinities (Ki) for the serotonin 5-HT1 and 5-HT2 receptors were 2,660 nM and 7,850 nM, respectively. 3-MA is also a weak agonist of the human trace amine-associated receptor 1 (TAAR1), with micromolar potency.

3-MA has similar effects in animal drug discrimination tests to PMA. It produced hyperlocomotion, a psychostimulant-like effect, in rodents similarly to amphetamine and PMA. It also produced hyperthermia and myoclonus, which are serotonin syndrome-associated effects, in rodents similarly to PMA.

Pharmacokinetics

The metabolism and metabolites of 3-MA have been described. It produces gepefrine (3-hydroxyamphetamine), a sympathomimetic agent, as one of its major metabolites.

Chemistry

Synthesis

The chemical synthesis of 3-MA has been described.

Analogues

The 2-aminoindane analogue of 3-MA is 5-methoxy-2-aminoindane (MEAI; 5-MeO-AI).

History

3-MA has appeared on the illicit market as a designer drug alternative to MDMA similarly PMA in the late 1980s and early 1990s, although far more rarely than PMA. Subsequently, it reappeared on the market, specifically via online sellers, in December 2021.

See also